
- Volume 0 0
FDA ISSUES WARNING REGARDING BIRTH CONTROL PATCH
The FDA recentlyannounced an updateto the product labelingfor the Ortho-Evracontraceptive patch.Information regardingthe risk of developingvenous thromboembolismhas beenchanged, based onincreased concerns that the patchincreases the risk of blood clots, comparedwith other types of birth controlwith similar ingredients. Two recentstudies produced conflicting dataregarding this issue, but the agencydetermined that the concerns weregreat enough to support the labelingchange.
The majority of women can use thepatch safely. The risk of embolic events,however, increases significantly withsmoking, high blood pressure, diabetes,high cholesterol, a family history of clottingdisorders, heart attack, stroke,chest pain, certain types of cancer,jaundice, or liver tumors. Womenshould consider an alternative methodof birth control if any of these conditionsexist.
Dr. Garrett is a clinical pharmacist practitioner at Cornerstone Health Care in High Point, NC.
Articles in this issue
almost 19 years ago
Cold Sore Outbreak?almost 19 years ago
Compounding with Commercial Drugs Can Cause Errorsalmost 19 years ago
compounding HOTLINEalmost 19 years ago
can you READ these Rxs?almost 19 years ago
Time to Share Accountabilityalmost 19 years ago
nacds SPEAKS OUT: One Voice Is Critical in Pharmacy Todayalmost 19 years ago
Use of Probiotics in the Management of Antibiotic-associated Diarrheaalmost 19 years ago
Labeling in Failure-to-Warn Casealmost 19 years ago
Ohio Prosecutors Fight Rx Abusealmost 19 years ago
Lean on Me: Help for the Impaired PharmacistNewsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.